Funding for this research was provided by:
Ministerie van Volksgezondheid, Welzijn en Sport (x)
Received: 27 February 2020
Accepted: 12 May 2020
First Online: 8 July 2020
Ethics approval and consent to participate
: All participants provided written consent and the study was approved by the medical ethics committee (VU University Medical Center, Amsterdam) under reference number 2009/022.
: Not applicable.
: RD has received fellowships from the Canadian Immunization Research Network (CIRN) and the Michael Smith Foundation of Health Research. JH, MJK, GSO, SD, AJK, JS, PJW, JAB, HEdM have no conflicts of interest. CJLM has received speakers’ fee from GSK, Qiagen, SPMSD/Merck, Roche, Menarini and Seegene, served occasionally on the scientific advisory board (expert meeting) of GSK, Qiagen, SPMSD/Merck., Roche and Genticel and was by occasion as consultant for Qiagen and Genticel. He is minority stock holder Self-Screen b.v., a spin off company of VUMC. Until 2014 he held a small number of certificates of shares in Delphi Biosciences, which went into receivership in 2014. Until April 2016 he holds minority stock of Diassay b.v.